Drugs / Adalimumab-680LT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06117423 | Mar → Dec 2024 | Crohn disease, ulcerative colitis | University Medical Center Groningen | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adalimumab-680LT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06117423 ↗ |
| Known as | adalimumab | “To gain better understanding of the drug targeting of adalimumab in IBD, the University Medical Center Groningen (UMCG) developed fluorescently labeled adalimumab (adalimumab-680LT).” NCT06117423 ↗ |
| Modality | Monoclonal antibody | “Adalimumab is a human monoclonal antibody against TNF-alpha” NCT06117423 ↗ |
| Route | Intravenous | “adalimumab-680LT was administered intravenously” NCT06117423 ↗ |